Regent Pacific Group Past Earnings Performance
Past criteria checks 0/6
Regent Pacific Group has been growing earnings at an average annual rate of 14.6%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 34.1% per year.
Key information
14.6%
Earnings growth rate
27.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | -34.1% |
| Return on equity | n/a |
| Net Margin | -8,607.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Regent Pacific Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -25 | 4 | 0 |
| 30 Sep 23 | 0 | -27 | 4 | 0 |
| 30 Jun 23 | 0 | -29 | 4 | 0 |
| 31 Mar 23 | 0 | -32 | 4 | 0 |
| 31 Dec 22 | 0 | -36 | 4 | 0 |
| 30 Sep 22 | 0 | -36 | 4 | -1 |
| 30 Jun 22 | 0 | -35 | 4 | -2 |
| 31 Mar 22 | 2 | -24 | 5 | -1 |
| 31 Dec 21 | 3 | -13 | 5 | 0 |
| 30 Sep 21 | 4 | -4 | 6 | 1 |
| 30 Jun 21 | 5 | 5 | 6 | 2 |
| 31 Mar 21 | 3 | -9 | 5 | 1 |
| 31 Dec 20 | 2 | -24 | 5 | 0 |
| 30 Sep 20 | 1 | -47 | 5 | 0 |
| 30 Jun 20 | 0 | -70 | 5 | 0 |
| 31 Mar 20 | 0 | -68 | 6 | 0 |
| 31 Dec 19 | 0 | -66 | 6 | 0 |
| 30 Sep 19 | 1 | -53 | 6 | 0 |
| 30 Jun 19 | 1 | -40 | 6 | 0 |
| 31 Mar 19 | 4 | -36 | 6 | 0 |
| 31 Dec 18 | 6 | -31 | 6 | 0 |
| 30 Sep 18 | 8 | -27 | 6 | 0 |
| 30 Jun 18 | 10 | -23 | 6 | 0 |
| 31 Mar 18 | 8 | -25 | 6 | 0 |
| 31 Dec 17 | 5 | -27 | 6 | 0 |
| 30 Sep 17 | 3 | -32 | 6 | 0 |
| 30 Jun 17 | 0 | -37 | 6 | 0 |
| 31 Mar 17 | 0 | -20 | 7 | 0 |
| 31 Dec 16 | 0 | -2 | 8 | 0 |
| 30 Sep 16 | 0 | 2 | 8 | 0 |
| 30 Jun 16 | 0 | 7 | 8 | 0 |
| 31 Mar 16 | 0 | -1 | 8 | 0 |
| 31 Dec 15 | 0 | -9 | 8 | 0 |
| 30 Sep 15 | 3 | -15 | 8 | 1 |
| 30 Jun 15 | 6 | -22 | 7 | 3 |
| 31 Mar 15 | 6 | -22 | 5 | 3 |
| 31 Dec 14 | 6 | -25 | 3 | 4 |
| 30 Sep 14 | 3 | -20 | 3 | 4 |
| 30 Jun 14 | 0 | -16 | 3 | 3 |
| 31 Mar 14 | 0 | -15 | 3 | 3 |
| 31 Dec 13 | 0 | -15 | 3 | 2 |
| 30 Sep 13 | 0 | -9 | 3 | 2 |
| 30 Jun 13 | 0 | -3 | 1 | 1 |
Quality Earnings: 575 is currently unprofitable.
Growing Profit Margin: 575 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 575 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare 575's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 575 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.3%).
Return on Equity
High ROE: 575's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.